- Conditions
- Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
- Interventions
- I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
- Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 21, 2026, 6:37 PM EDT